Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. metabolic dysfunction
Show results for
Products
Software
Applications

Companies

News
Articles

Refine by
Date

  • Older

Metabolic Dysfunction Articles & Analysis

8 news found

Ace Therapeutics Launches In Vivo Models of Diabetes Mellitus to Enhance Diabetes Research Outcomes

Ace Therapeutics Launches In Vivo Models of Diabetes Mellitus to Enhance Diabetes Research Outcomes

Thus, researchers can conduct thorough investigations on the course of diabetes, metabolic dysfunction, and possible treatment options. “We are excited to provide in vivo models of diabetes mellitus, which represent a significant leap forward in diabetes research,” said the marketing manager of Ace Therapeutics. ...

ByAce Therapeutics


NeuroPointDX to Present Precision Medicine Approaches to Diagnosing and Treating Autism at National TACA Autism Conference

NeuroPointDX to Present Precision Medicine Approaches to Diagnosing and Treating Autism at National TACA Autism Conference

This enabled the identification of metabolic subtypes that indicate an increased risk of an ASD diagnosis. ...

ByNeuroPointDX


Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen

Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen

Grade 3 or higher events that may be associated with CRS include hypotension, hypoxia, hyperbilirubinemia, hypofibrinogenemia, acute respiratory distress syndrome (ARDS), atrial fibrillation, hepatocellular injury, metabolic acidosis, pulmonary edema, multiple organ dysfunction syndrome and HLH/MAS. ...

ByBristol Myers Squibb Corporate


Fractyl Health Announces Publication of Pioneering New Model of Intestine’s Role in Metabolism

Fractyl Health Announces Publication of Pioneering New Model of Intestine’s Role in Metabolism

LEXINGTON, Mass., October 27, 2021 – Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, including type 2 diabetes (T2D), today announced the publication of an innovative new model of metabolism, the Metabolic Balance Model. The study synthesizes ...

ByFractyl Health


Fractyl Announces Tenth Trial Site Opened in REVITA-T2Di Study of Revita DMR for Type 2 Diabetes

Fractyl Announces Tenth Trial Site Opened in REVITA-T2Di Study of Revita DMR for Type 2 Diabetes

DMR Treatment Revita DMR is based on Fractyl’s breakthrough insights surrounding the role of the gut in metabolic diseases. An outpatient endoscopic procedure, Revita DMR resurfaces the lining of the upper intestine (duodenal mucosa). ...

ByFractyl Health


Fractyl Announces First Patient Enrolled in Pivotal Study of Novel Procedural Therapy Revita® DMR for Type 2 Diabetes

Fractyl Announces First Patient Enrolled in Pivotal Study of Novel Procedural Therapy Revita® DMR for Type 2 Diabetes

(Fractyl), a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, today announced the enrollment of the first patient in a pivotal clinical trial of Revita® DMR for patients with type 2 diabetes. ...

ByFractyl Health


Fractyl Announces Publication of Clinical Results from INSPIRE Study Showing Durable Insulin-Free Glycemic Control in Majority of Patients Treated

Fractyl Announces Publication of Clinical Results from INSPIRE Study Showing Durable Insulin-Free Glycemic Control in Majority of Patients Treated

“Revita DMR is based on Fractyl’s revolutionary scientific insights surrounding the role of the gut in metabolic diseases. This study provides further support that targeting the gut with a single treatment of Revita DMR can transform metabolic ...

ByFractyl Health


Results from Axial Therapeutics Phase1b/2a Study of AB-2004 in Adolescents with Autism Spectrum Disorder Met Primary Endpoint and Reduced Irritability and Other Symptoms

Results from Axial Therapeutics Phase1b/2a Study of AB-2004 in Adolescents with Autism Spectrum Disorder Met Primary Endpoint and Reduced Irritability and Other Symptoms

Comorbidities are extensive and diverse, and include GI dysfunction, irritability, anxiety, ADHD, metabolic abnormalities, allergies, autoimmune disorder, neuroinflammation and epilepsy. GI dysfunction is estimated to occur in 40 to 70% of individuals with ASD. ...

ByAxial Therapeutics Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT